|
Name |
6H-Dibenzo(b,d)pyran-2,6(4ah)-dione, 3,7-dihydroxy-9-methoxy-4a-methyl-, (4aS)-
|
| Molecular Formula | C15H12O6 | |
| IUPAC Name* |
(4aS)-3,7-dihydroxy-9-methoxy-4a-methylbenzo[c]chromene-2,6-dione
|
|
| SMILES |
C[C@]12C=C(C(=O)C=C1C3=C(C(=CC(=C3)OC)O)C(=O)O2)O
|
|
| InChI |
InChI=1S/C15H12O6/c1-15-6-12(18)10(16)5-9(15)8-3-7(20-2)4-11(17)13(8)14(19)21-15/h3-6,17-18H,1-2H3/t15-/m0/s1
|
|
| InChIKey |
YWYZLBQRCUAQAV-HNNXBMFYSA-N
|
|
| Synonyms |
dehydroaltenusin; 31186-13-7; Altenusin, dehydro-; 6H-Dibenzo(b,d)pyran-2,6(4ah)-dione, 3,7-dihydroxy-9-methoxy-4a-methyl-, (4aS)-; U0VV30G3Y4; (S)-Dehydroaltenusin; UNII-U0VV30G3Y4; HY-100513A; CS-0019645; (4aS)-3,7-dihydroxy-9-methoxy-4a-methylbenzo[c]chromene-2,6-dione; 3,7-dihydroxy-9-methoxy-4a-methyl-4aH-benzo(c)chromene-2,6-dione
|
|
| CAS | 31186-13-7 | |
| PubChem CID | 14824648 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 288.25 | ALogp: | 1.7 |
| HBD: | 2 | HBA: | 6 |
| Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 93.1 | Aromatic Rings: | 3 |
| Heavy Atoms: | 21 | QED Weighted: | 0.77 |
| Caco-2 Permeability: | -4.638 | MDCK Permeability: | 0.00004120 |
| Pgp-inhibitor: | 0.008 | Pgp-substrate: | 0 |
| Human Intestinal Absorption (HIA): | 0.033 | 20% Bioavailability (F20%): | 0.334 |
| 30% Bioavailability (F30%): | 0.701 |
| Blood-Brain-Barrier Penetration (BBB): | 0.17 | Plasma Protein Binding (PPB): | 77.95% |
| Volume Distribution (VD): | 0.711 | Fu: | 10.66% |
| CYP1A2-inhibitor: | 0.964 | CYP1A2-substrate: | 0.806 |
| CYP2C19-inhibitor: | 0.293 | CYP2C19-substrate: | 0.349 |
| CYP2C9-inhibitor: | 0.367 | CYP2C9-substrate: | 0.57 |
| CYP2D6-inhibitor: | 0.588 | CYP2D6-substrate: | 0.2 |
| CYP3A4-inhibitor: | 0.823 | CYP3A4-substrate: | 0.176 |
| Clearance (CL): | 12.059 | Half-life (T1/2): | 0.282 |
| hERG Blockers: | 0.022 | Human Hepatotoxicity (H-HT): | 0.265 |
| Drug-inuced Liver Injury (DILI): | 0.574 | AMES Toxicity: | 0.556 |
| Rat Oral Acute Toxicity: | 0.684 | Maximum Recommended Daily Dose: | 0.823 |
| Skin Sensitization: | 0.652 | Carcinogencity: | 0.835 |
| Eye Corrosion: | 0.023 | Eye Irritation: | 0.307 |
| Respiratory Toxicity: | 0.916 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC002837 | ![]() |
0.608 | D07MGA | ![]() |
0.311 | ||
| ENC002171 | ![]() |
0.606 | D06GCK | ![]() |
0.273 | ||
| ENC005309 | ![]() |
0.586 | D0C1SF | ![]() |
0.258 | ||
| ENC004059 | ![]() |
0.551 | D06TJJ | ![]() |
0.240 | ||
| ENC003953 | ![]() |
0.520 | D04UTT | ![]() |
0.239 | ||
| ENC003954 | ![]() |
0.520 | D04AIT | ![]() |
0.237 | ||
| ENC002647 | ![]() |
0.520 | D09WKB | ![]() |
0.233 | ||
| ENC005362 | ![]() |
0.520 | D08CCE | ![]() |
0.232 | ||
| ENC002173 | ![]() |
0.520 | D0K8KX | ![]() |
0.232 | ||
| ENC004851 | ![]() |
0.520 | D0N1FS | ![]() |
0.226 | ||